---
title: 'The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing
  tumour-agnostic potential of molecularly guided therapies and for steering drug
  development'
date: '2024-08-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39187421/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240827181517&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: The ESMO Tumour-Agnostic Classifier (ETAC) focuses on the
  interplay of targeted driver molecular aberration and tumour-specific biology modulating
  the therapeutic effect of MGTOs. We propose minimum requirements to screen for tumour-agnostic
  potential (ETAC-S) as part of tumour-agnostic drug development. Definition of ETAC
  cut-offs is ...'
disable_comments: true
---
CONCLUSION: The ESMO Tumour-Agnostic Classifier (ETAC) focuses on the interplay of targeted driver molecular aberration and tumour-specific biology modulating the therapeutic effect of MGTOs. We propose minimum requirements to screen for tumour-agnostic potential (ETAC-S) as part of tumour-agnostic drug development. Definition of ETAC cut-offs is ...